{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"LN-144"},{"type":"Synonym","name":"autologous TIL LN-144"},{"type":"Synonym","name":"Contego"},{"type":"Synonym","name":"autologous tumor infiltrating lymphocytes LN-144"},{"type":"USBrandName","name":"Amtagvi"},{"type":"CASRegistryName","name":"2306267-74-1"}],"definition":{"html":"A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.","text":"A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/lifileucel","text":"Lifileucel"},"nciConceptId":"C120552","nciConceptName":"Lifileucel","termId":769186,"name":"lifileucel","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lifileucel"}],"links":null}